ThomasNet News Logo
Sign Up | Log In | ThomasNet Home | Promote Your Business

BIO Applauds prescription change communication legislation.

Print | 
Email |  Comment   Share  
January 29, 2014 - BIO and Washington Biotechnology & Biomedical Association commend Washington State House and Senate for advancing legislation – HB 2326 and SB 6091 – designed to create pathway for substitution of interchangeable biologic medicines. Endorsed by broad coalition of biologic and biosimilar manufacturing companies, legislation represents significant step forward, ensures transparency and communication between patients and their treatment teams, and is consistent with BIO principles.

Legislation Introduced to Communicate Prescription Changes to Patients and Physicians


Biotechnology Industry Organization
1201 Maryland Ave., SW, Ste. 900
Washington, DC, 20024
USA



Press release date: January 22, 2014

Patients Should Be Informed if Doctor's Prescription Changed

WASHINGTON--The Biotechnology Industry Organization (BIO) and the Washington Biotechnology & Biomedical Association (WBBA) commend the Washington State House and Senate for continuing to advance legislation designed to create a pathway for the substitution of interchangeable biologic medicines.

The policies outlined in the identical HB 2326 and SB 6091 align with BIO’s principles on biologic substitution, therefore BIO and WBBA support passage of these bills.

Although similar bills have been addressed in other states, HB 2326 and SB 6091 represent the first legislative effort of their kind to be endorsed by a broad coalition of both biologic and biosimilar manufacturing companies. The legislation includes transparent communication on all biologic medicines dispensed in order to maintain a consistent and complete medical record. This legislation represents a significant step forward, ensures transparency and communication between patients and their treatment teams, and is fully consistent with the BIO principles.

While the U.S. Food and Drug Administration (FDA) oversees approval of biologic medicines and designation of interchangeability, policies governing whether one product may be substituted in place of a doctor's prescription and whether a pharmacist must inform patients and doctors are covered by state law. HB 2326 and SB 6091 seek to properly preserve patient access to accurate prescription information, maintain incentives for innovation and promote a competitive market for biologic therapies. BIO will continue to advocate for full transparency in the substitution process as patients and their physicians should have the right to know what biologic medicine the patient receives from the pharmacy. Bills such as this, that properly addresses the important aspect of physician communication, represent model legislation necessary in all 50 states to address this cutting-edge technology.

The FDA is currently developing a pathway for the development and approval of safe and effective interchangeable biologic products in the United States. However, there is still a major role for states to play in ensuring substitution practices remain transparent and physicians remain engaged in the process.

Interchangeable biologics are not generics. Even slight changes to a biologic drug can change its properties entirely. Unlike conventional generic medicines, interchangeable biologics are not the same as the drugs they seek to substitute. In fact, two biologics made using different cell lines and differing manufacturing processes will rarely, if ever, be exactly the same. Those suggesting interchangeable biologics and generics are the same are wrong.

Patients and physicians managing chronic conditions are generally aware of which biologic treatments work best in their unique circumstances. Providing information about substitution to patients and physicians allows everyone involved the opportunity to discuss past treatment experiences so that any possible unexpected issues can be better understood and avoided.

As the Washington State Legislature continues to address issues related to biologic substitution, BIO and WBBA encourage policy makers to continue to put patients first.

About WBBA

The Washington Biotechnology & Biomedical Association (WBBA) has over 640 member organizations and is an independent, non-profit 501(c)(6) trade association serving the life sciences industry in the state of Washington. It is completely resourced and supported by its members, including organizations engaged in, or supportive of, research, development and commercialization of life science innovation. http://www.washbio.org

About BIO

BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIO produces BIOtechNOW, an online portal and monthly newsletter chronicling “innovations transforming our world.” Subscribe to BIOtechNOW.

Contacts

Biotechnology Industry Organization
George Goodno, 202-962-6660
Web: www.bio.org
Blog: www.biotech-now.org
Twitter: @IAmBiotech
Print | 
Email |  Comment   Share  
Contacts: View detailed contact information.


 

Post a comment about this story

Name:
E-mail:
(your e-mail address will not be posted)
Comment title:
Comment:
To submit comment, enter the security code shown below and press 'Post Comment'.
 



 See related product stories
More .....
 See more product news in:
Services
| Featured Manufacturing Jobs
 Other News from this company:
Senator Blunt Honored as BIO Legislator of the Year
Congressman Holt Honored as BIO Legislator of the Year
The Biotechnology Industry Organization and Biominas Brasil to Co-Host First Ever BIO Latin America Conference
Synthetic Biology Breaks New Ground on Renewable Chemicals
Partnering Opens for 2014 BIO International Convention with Record Number of Meetings Expected
More ....
 Tools for you
Watch Company 
View Company Profile
Company web site
More news from this company
E-mail this story to a friend
Save Story
Search for suppliers of
Trade Associations


Home  |  My ThomasNet News®  |  Industry Market Trends®  |  Submit Release  |  Advertise  |  Contact News  |  About Us
Brought to you by Thomasnet.com        Browse ThomasNet Directory

Copyright © 2014 Thomas Publishing Company. All Rights Reserved.
Terms of Use - Privacy Policy



Error close

Please enter a valid email address